Introduction
Materials and methods
Data sources
Research team | A palliative nurse (MRV) A dentist (JSD) A medical doctor (DR) \ A healthcare researcher (ZR) |
---|---|
Data bases | Sciencedirect, PubMed, Google scholar, Ovid and EBSCOhost |
Other resources | Reference list and manual search in key journals |
Search time | January 2000 to December 2017 |
Language | Primary studies in English language |
Search terms | “oral condition” OR “oral disease” OR “dental disease” OR “mouth disease” OR “mouth condition” OR mucositis OR stomatitis OR candidiasis OR cheilitis OR xerostomia OR “periodontal disease” OR halitosis OR thrush OR “angular cheilitis” OR “denture stomatitis” OR gingivitis OR periodontitis OR “mouth ulcer” OR “aphthous ulcer” AND palliative OR terminally-ill OR “terminally ill” OR “advanced disease” OR “advanced illness” OR dying OR end-of-life OR hospice OR cancer AND treatment OR intervention OR therapy OR management OR “oral care” OR “mouth care” OR “dental management” AND “end-of-life care” |
Study selection
Data extraction
Assessment of study quality
Data analysis
Results
Characteristics of study
Author(s)/Year | Title | Purpose | Setting | Participants | Study design | Oral conditions present |
---|---|---|---|---|---|---|
Nakajima /2017 | Characteristics of Oral Problems and Effects of Oral Care in Terminally Ill Patients With Cancer | To investigate oral problems in terminal stage of cancer and improvement of dry mouth by oral care. | Japan | Terminally-ill cancer patients | Quantitative descriptive | 1. Dry mouth 2. Stomatitis 3. Candidiasis |
Fischer et al./2014 | Oral health conditions affect functional and social activities of terminally ill cancer patients | To characterize oral conditions in terminally ill cancer patients to determine the presence, severity, and the functional and social impact of these oral conditions. | United States of America | Terminally-ill cancer patients | Quantitative descriptive | Using standardized oral examination: 1. Salivary hypofunction 2. Mucosal erythema 3. Ulceration 4. Fungal infection Using Oral Problem Scale (OPS): 1. Xerostomia 2. Orofacial pain 3. Taste change |
Amodio et al./2014 | Oral health after breast cancer treatment in postmenopausal women | To characterize oral health in postmenopausal breast cancer survivors. | Brazil | Post-menopausal breast cancer survivors | Quantitative descriptive | 1. Chronic periodontal disease |
Qutob et al. /2013 | Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment | To implement a standardized hospital oral care protocol and record the incidence of oral mucositis for inpatients with childhood cancer. | Australia | Pediatric patients with cancer | Quantitative descriptive | 1. Mucositis |
Velten et al./2017 | Prevalence of oral manifestations in children and adolescents with cancer submitted to chemotherapy | To evaluate changes in oral lesions during follow-up of children and adolescents in chemotherapy | Brazil | Children and adolescents with cancer | Quantitative descriptive | 1. Mucositis 2. Xerostomia 3. Cold sores 4. Candidiasis |
Ezenwa et al./2016 | Caregivers’ perspectives on oral health problems of end-of-life cancer patients | To determine caregivers’ perspectives on oral health problems in cancer patients at the end of life and explore factors that contribute to those perspectives. | United States of America | Advanced cancer patients | Quantitative descriptive | 1. Xerostomia 2. Orofacial pain 3. Taste change |
Mercadante et al./2015 | Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. | To determine the prevalence and the characteristics of oral symptoms in a large population of advanced cancer patients. | Argentina | Advanced cancer patients | Quantitative descriptive | 1. Mucositis 2. Dry mouth 3. Dysphagia |
Matsuo et al./2016 | Associations between oral complications and days to death in palliative care patients | To investigate the associations between the incidence of oral problems and the days to death (DTD) in patients receiving palliative care. | Japan | Patients receiving palliative care | Quantitative descriptive | 1. Dental caries 2. Gingival inflammation 3. Tongue coating 4. Candidiasis 5. Tongue inflammation 6. Dry mouth 7. Bleeding spots |
Kvalheim et al./2016 | End-of-life palliative oral care in Norwegian health institutions. An exploratory study. | To explore circumstances surrounding procedures and knowledge regarding oral care for terminal patients in Norwegian healthcare institutions. | Norway | Nurses for end-of-life patients | Quantitative descriptive | 1. Dry mouth 2. Plaque 3. Food particles and fungus Infections 4. Sores and scab 5. Viscous ropy saliva and chapped lips 6. Reduced appetite and pain 7. Dysphagia 8. Halitosis 9. Coughing and problems using dentures |
Bogaardt et al./2015 | Swallowing problems at the end of the palliative phase: incidence and severity in 164 unsedated patients. | To establish the incidence of swallowing problems and related problems in the dying phase | Netherlands | Dying patients | Quantitative descriptive | 1. Swallowing problems 2. Frequent coughing 3. Problems with oral secretions |
Meidell et al./ 2009 | Acupuncture as an optional treatment for hospice patients with xerostomia: an intervention study | To investigate the feasibility of conducting a 5-week acupuncture intervention in a hospice, and the effect of acupuncture on xerostomia, dysphagia and dysarthria in patients with terminal cancer. | Sweden | End-of-life patients | Quantitative comparative | 1. Xerostomia 2. Dysphagia 3. Dysarthria |
Lagman et al./2017 | Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients. | To assess the efficacy of a single-dose fluconazole 150 mg for oral thrush. | United States of America | Palliative and hospice patients with advanced cancer and have a clinical diagnosis of oral thrush | Quantitative descriptive | 1. Oral thrush |
Momo et al., 2017 | Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy | To assess the efficacy and safety of indomethacin (IM) oral spray (OS) as a pain control therapy for oropharyngeal mucositis due to anticancer chemo- and radiotherapy | Japan | Patients with head and neck carcinomas and haematological tumours | Quantitative comparative | 1. Mucositis |
Ling & Larsson/ 2011 | Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy | To assess the effect of pharmacological treatment in head and neck cancer patients with OM-induced pain and swallowing difficulties. | Sweden | Patients with head and neck cancer undergoing radiotherapy | Quantitative descriptive | 1. Mucositis 2. Pain 3. Swallowing difficulties |
Gligorov et al./2011 | Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study. | To evaluate the prevalence of oropharyngeal candidiasis (OPC) in cancer patients treated with chemotherapy and/or radiotherapy. | France | Cancer patients treated with chemotherapy and/or radiotherapy | Quantitative descriptive | 1. Oropharyngeal candidiasis 2. Mucositis 3. Xerostomia 4. Taste changes 5. Pain |
Davies et al./2006 | Oral candidosis in patients with advanced cancer | To determine the epidemiology, aetiology, clinical features and microbiological aspects of oral candidosis in a cohort of cancer patients receiving specialist palliative care. | United Kingdom | Cancer patients receiving specialist palliative care. | Quantitative descriptive | 1. Oral yeast carriage 2. Oral candidiasis 3. Xerostomia |
Wilberg et al./2012 | Oral health is an important issue in end-of-life cancer care. | To assess the prevalence of oral morbidity in patients receiving palliative care for cancers outside the head and neck region and to investigate if information concerning oral problems was given. | Norway | Cancers patients outside the head and neck region | Qualitative interview | 1. Xerostomia 2. Mucosal friction 3. General oral discomfort 4. Taste changes 5. Candidiasis |
Rydholm & Strang/2002 | Physical and psychosocial impact of xerostomia in palliative cancer care: a qualitative interview study | To explore the global effects of xerostomia, with a specific focus on psychological and social consequences. | Sweden | Patients with advanced malignancies and symptomatic xerostomia | Qualitative interview | 1. Subjective discomfort 2. Dryness or burning sensation 3. Loss of function e.g. articulation or swallowing 4. Increased infection (oral thrush and ulcerations) |
Rohr et al./2010 | Oral discomfort in palliative care: results of an exploratory study of the experiences of terminally ill patients. | To examine oral discomfort from the perspective of terminally ill patients. | Australia | Terminally-ill patients | Qualitative interview | 1. Xerostomia 2. Bouts of ulceration and infection |
Common oral conditions among palliative patients
Multifaceted impact of oral conditions in palliative patients
Study | Findings associating oral conditions and its social and/or functional impact | |
---|---|---|
Social | Functional | |
Fischer et al. | Orofacial pain and salivary hypofunction had significant associations with social impact (p < 0.001) such as worrisome that affected the patients’ social interactions. | Xerostomia (p < 0.001), orofacial pain (p < 0.001), salivary hypofunction (p < .001) and taste change (p = 0.042) had significant associations with functional impact, which was possibly related to food enjoyment. |
Ezenwa et al. | Xerostomia, orofacial pain and taste change had social impact of feeling worried, bothered, not wanting people around and a feeling of less satisfying life, with percentage agreement ranged from 41 to 64% between caregivers and care recipients. However, a significant difference in the means of the social impact subscale was reported between the two groups (p = 0.02), with caregivers overestimating social impact. | Xerostomia, orofacial pain and taste change had functional impact which include swallowing difficulty, speaking difficulty, eating difficulty, food restriction, dryness and pain, with significant correlation between caregivers’ and care recipients’ ratings (p < 0.001) |
Rydholm & Strang | Xerostomia was reported to have psychosocial effects, including shame, increased feelings of being a patient rather than a person and a tendency to avoid social contact, resulting in loneliness. | Xerostomia was reported to be associated with loss of oral function, such as in articulation and swallowing. |
Rohr et al. | Orofacial pain prevent patient from sharing and enjoying meals with friends and family, which limit their social outings and participation at special occasions. Participants were more ‘tentative’ in holding a conversation with others due to speech difficulties, hence avoiding ‘close physical contact’ with their loved ones. | Xerostomia was described as ‘constantly there’, causing swallowing difficulties and loss of taste. Difficulty of swallowing was also described as ‘unbearable at times’. |
Wilberg et al. | Xerostomia and taste alterations were associated with anxiety (p = 0.04) and depression (p = 0.34) | n/a |
Management of oral conditions among palliative patients
Oral condition | Study | Management | Effectiveness |
---|---|---|---|
Xerostomia | Mercadante et al. | Drug medication • Opioids • Corticosteroids • Diuretics • Benzodiazepines • Anticonvulsants • Neuropletics • Nonsteroidal anti-inflammatory drugs Medical treatment • Chlorexidine • antifungal drugs • Benzydamine • Natural agents | n/a |
Kvalheim et al. | Lubricating lips • Eucerin liniment • Glycerol • Vaseline • Blisex • Lypsyl • Lip stick • Lip cream Lubricating mucosa • Glycerol • Glycerol solution 17% • Glycerol solution 50% • Glycerol solution 70% • Glycerol with peppermint oil • Glycerol and Chlorhexidine • Xylocaine/Lidocaine viscous • Xylocaine/Lidocaine viscous • Paracetamol mixture and cream • Panodil mixture and cream 1:1 • Pure cream • Zendium saliva • Zendium gel • Groundnut oil • Saliva gel • Oralbalance • Mouth moisturiser | n/a | |
Meidell & Rasmussen | Acupuncture treatment twice a week for 5 weeks – a total of ten treatments. | Measurements were using visual analogue scale (VAS), consisted of a horizontal line, 0–10 cm, where 0 represented no problem or discomfort and 10 represented severe problems and discomfort. The feeling of dryness of the mouth declined for all the participants as the series of treatment proceeded. In most cases a substantial improvement could not be noted until after fifth treatments. VAS decreased from 7.5 to 4.8 after fifth treatments (P < 0.001). Between the sixth and tenth treatments, the VAS decreased from 4.8 to 3.3 (P < 0.001). The VAS decreased from 7.5 before the baseline to 3.3 before the tenth treatment (P < 0.001). | |
Nakajima | Standard oral care by nursing staff of the wards, which include moisturizing, brushing, and oral cleaning (such as tongue coating removal) or oral massage performed by ward staff on a regular basis to resolve dry mouth). Intervention by specialist oral care team (specialist oral care) was performed as needed. | The rate of dry mouth improvement by oral care intervention was investigated by the severity (Grade 1, 2 and 3). All grade 1 cases were improved by standard oral care (100%). Grade 2 dry mouth was improved by standard oral care in 85% in good oral intake group (oral food intake was 30% or more) and 71% in poor oral intake group (oral food intake was less than 30%). Six ineffective cases of poor oral intake group were treated with specialist oral care, resulting in an improvement rate of 83%. Grade 3 dry mouth was improved by standard oral care in 40% in good oral intake group, and 2 ineffective cases were treated with specialist oral care, resulting in an improvement rate of 80%. In poor oral intake group, improvement was achieved by standard oral care in 67%, and 8 ineffective cases were treated with specialist oral care, resulting in an improvement rate of 81%. Thus, these interventions improved dry mouth in 80% or more of the patients both in good oral intake group and in poor oral intake group. | |
Candidiasis | Lagman et al. | A single-dose fluconazole 150 mg via mouth | Majority had complete response, except 2 who did not respond to treatment. Probable side effects of the medication included nausea in 4 patients, abdominal pain in 1, and diarrhea in 1. Both the change in the number of symptoms and the symptom scores before and after treatment decreased significantly (P < 0.001). |
Gligorov et al. | Local antifungal treatments were prescribed in 123 (75%) patients. Amphotericin B mouthwashes were administered in 67 (54.5%) patients, miconazole mucoadhesive buccal tablet in 36 patients (29.3%), and nystatin mouthwashes in 20 (16.3%) patients. Fluconazole, an oral systemic treatment, was prescribed in 41 (25%) patients at a dosage of 50 mg/day, 100 mg/day, and 200 mg/day in 7 (17.7%), 22 (53.7%), and 10 (24.4%) patients, respectively. Concomitant non-antifungal treatments were prescribed in 57 (35%) patients, mainly sodium bicarbonate mouthwashes in 45 patients. | Miconazole MBT was reported to be “efficacious” or “very efficacious” in 25 of 32 patients (78.1%) vs. 39 of 51 (76.5%) for amphotericin B, and 9 of 15 60%) for nystatin. The nonefficacy reported by the patients was related to noncompliance to treatment; 30% of noncompliant patients vs. 14.3% of those compliant rated amphotericin B as “slightly efficacious or not efficacious.” | |
Dysphagia | Meidell & Rasmussen | Acupuncture treatment twice a week for 5 weeks – a total of ten treatments. | Measurements were using visual analogue scale (VAS), consisted of a horizontal line, 0–10 cm, where 0 represented no problem or discomfort and 10 represented severe problems and discomfort. A substantial improvement of dysphagia was not obvious until after fifth treatments when the VAS had decreased from 5.6 to 4.1 (P < 0.001). Between the sixth and tenth treatments, the VAS decreased from 4.1 to 3.7 (P = 0.81). The VAS decreased from 5.6 before the baseline to 3.7 before the tenth treatment (P = 0.01). |
Ling & Larsson | Step-based pharmacological intervention 1. Acetaminophen 2. NSAID 3. Opioids 4. Adjuvant medication - Amitryptilin, gabapentin, or pregabalin were considered due to neurotic pain, mainly tumor-related. - Betametasone was considered for optimized anti-inflammatory effect, impaired general condition, or antiemetic effect. Topically acting drugs - Lidocain and benzydamine were prescribed at RT start by the dental services at the hospital to all patients with an irradiated mouth. | Soreness in the mouth showed unexpectedly significant worsening (P = 0.001) between baseline (TQ1) and 1 week later (TQ2). Significant worsening was found for three swallowing questions about liquids (P = 0.007) and solid food (P = 0.004), choking when swallowing (P = 0.018). | |
Mucositis | Ling & Larsson | Step-based pharmacological intervention 1.Acetaminophen 2.NSAID 3.Opioids 4.Adjuvant medication - Amitryptilin, gabapentin, or pregabalin were considered due to neurotic pain, mainly tumor-related. - Betametasone was considered for optimized anti-inflammatory effect, impaired general condition, or antiemetic effect. Topically acting drugs Lidocain and benzydamine were prescribed at RT start by the dental services at the hospital to all patients with an irradiated mouth. | Four oral mucositis (OM) grades were used: 0: No reaction 1: Hyperaemia, impressions, soreness, edema 2: Erythema, occasional ulcers, soreness 3: Painful erythema, larger fibrin-coated ulcers 4: Widespread ulcerated areas, easily bleeding, very painful In the early intervention (EI) group, the OM grade increased between baseline (TQ1) and 1 week later (TQ2) (P < 0.001). In the late intervention (LI) group, the OM grade was unchanged between TQ1 and TQ2 (P = 0.059). |
Momo et al. | Indomethacin (IM) oral spray (OS) | Pain relief was achieved in 93% patients at 25 (5–60) min after applying the IM-OS preparation (15.6 ± 3.4 μg/kg) and analgesic effects were maintained for 120 (10–360) min. The pain was significantly decreased after using the spray (3.6 ± 0.7 vs. 2.4 ± 0.9, p < 0.01). Moreover, urinary IM excretion rates after applying the IM spray preparation were 1.8 ± 0.8% of the IM oral spray dose (130.5 ± 77.7 μg/kg/day), which was markedly lower than that following oral administration of IM (60%). No adverse events were observed following application of the spray. |
Treatment challenges of oral conditions in palliative patients
Study | Challenges |
---|---|
Kvalheim et al. | • Lack of knowledge/experience/routine (43%) • Lack of patient cooperation (38%) • Oral problems were not prioritised (22%) • Difficult access to the mouth (11%), • Lack of resources by (8%) • Retching (3%). |
Bogaardt et al | • Nursing staff rated the incidence and severity of swallowing problems lower than the relatives (p < 0.0001) • Nursing staff rated the median severity of frequent coughing (p = 0.012) and loss of appetite (p = 0.001) significantly lower compared to the relatives’ |